Wedmont Private Capital Has $172,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wedmont Private Capital increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 11.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,943 shares of the company’s stock after acquiring an additional 2,000 shares during the period. Wedmont Private Capital’s holdings in Recursion Pharmaceuticals were worth $172,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Swiss National Bank boosted its holdings in shares of Recursion Pharmaceuticals by 1.6% in the 3rd quarter. Swiss National Bank now owns 284,100 shares of the company’s stock valued at $2,173,000 after purchasing an additional 4,600 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at about $117,000. Charles Schwab Investment Management Inc. grew its position in Recursion Pharmaceuticals by 15.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock valued at $8,858,000 after acquiring an additional 157,189 shares during the last quarter. UBS Group AG raised its stake in Recursion Pharmaceuticals by 103.1% during the third quarter. UBS Group AG now owns 342,679 shares of the company’s stock worth $2,621,000 after acquiring an additional 173,954 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Recursion Pharmaceuticals by 15.4% in the 3rd quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock valued at $457,000 after purchasing an additional 7,973 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $10.10, for a total transaction of $404,000.00. Following the completion of the sale, the chief executive officer now owns 1,043,524 shares of the company’s stock, valued at approximately $10,539,592.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 3,000 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the sale, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,701,312.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $10.10, for a total value of $404,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,043,524 shares of the company’s stock, valued at $10,539,592.40. The disclosure for this sale can be found here. Insiders sold 281,359 shares of company stock worth $2,410,876 over the last ninety days. 15.75% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Friday, May 10th. KeyCorp upped their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $8.85 on Monday. The company has a 50 day simple moving average of $8.74 and a 200 day simple moving average of $9.92. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $16.75. The firm has a market cap of $2.10 billion, a PE ratio of -5.53 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. Recursion Pharmaceuticals’s revenue was up 14.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.34) earnings per share. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.